[go: up one dir, main page]

DE69637156D1 - Dna-molekül, herstellung und verwendung in der gentherapie - Google Patents

Dna-molekül, herstellung und verwendung in der gentherapie

Info

Publication number
DE69637156D1
DE69637156D1 DE69637156T DE69637156T DE69637156D1 DE 69637156 D1 DE69637156 D1 DE 69637156D1 DE 69637156 T DE69637156 T DE 69637156T DE 69637156 T DE69637156 T DE 69637156T DE 69637156 D1 DE69637156 D1 DE 69637156D1
Authority
DE
Germany
Prior art keywords
manufacture
gene therapy
dna molecule
genes
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637156T
Other languages
English (en)
Other versions
DE69637156T2 (de
Inventor
Beatrice Cameron
Joel Crouzet
Anne-Marie Darquet
Daniel Scherman
Pierre Wils
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69637156(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE69637156D1 publication Critical patent/DE69637156D1/de
Publication of DE69637156T2 publication Critical patent/DE69637156T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69637156T 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie Expired - Lifetime DE69637156T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9502117A FR2731014B1 (fr) 1995-02-23 1995-02-23 Molecules d'adn, preparation et utilisation en therapie genique
FR9502117 1995-02-23
PCT/FR1996/000274 WO1996026270A1 (fr) 1995-02-23 1996-02-21 Molecules d'adn, preparation et utilisation en therapie genique

Publications (2)

Publication Number Publication Date
DE69637156D1 true DE69637156D1 (de) 2007-08-23
DE69637156T2 DE69637156T2 (de) 2008-02-07

Family

ID=9476445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69637156T Expired - Lifetime DE69637156T2 (de) 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie

Country Status (19)

Country Link
US (3) US6143530A (de)
EP (1) EP0815214B1 (de)
JP (1) JPH11500618A (de)
KR (1) KR19980702406A (de)
AT (1) ATE366806T1 (de)
AU (1) AU709111B2 (de)
BR (1) BR9607273A (de)
CA (1) CA2211427C (de)
CZ (1) CZ266897A3 (de)
DE (1) DE69637156T2 (de)
FI (1) FI973467A0 (de)
FR (1) FR2731014B1 (de)
HU (1) HUP9801216A3 (de)
IL (1) IL117214A0 (de)
MX (1) MX9706109A (de)
NO (1) NO973838L (de)
SK (1) SK114397A3 (de)
WO (1) WO1996026270A1 (de)
ZA (1) ZA961484B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
NZ504214A (en) 1997-10-24 2003-06-30 Invitrogen Corp Recombination cloning using nucleic acids having recombination sites
FR2776669B1 (fr) * 1998-03-24 2001-06-15 Rhone Poulenc Rorer Sa Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
CA2323831A1 (fr) * 1998-03-24 1999-09-30 Aventis Pharma S.A. Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
WO2000056901A2 (en) 1999-03-24 2000-09-28 Board Of Regents, The University Of Texas System Linear and circular expression elements
US6746870B1 (en) * 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
DE19941186A1 (de) * 1999-08-30 2001-03-01 Peter Droege Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
ES2245656T3 (es) * 1999-12-30 2006-01-16 Aventis Pharma S.A. Utilizacion de un vector que comprende un acido nucleico que codifica un factor anti-angiogeno para el tratamiento de las neovascularizaciones de la cornea.
NZ522860A (en) * 2000-05-26 2004-09-24 Gencell S Purification of a triple helix formation with an immobilized oligonucleotide
AU2001277076A1 (en) * 2000-07-21 2002-02-05 The United States Of America As Represented By The Secretary Of Agriculture Methods for the replacement, translocation and stacking of DNA in eukaryotic genomes
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
IL158017A0 (en) * 2001-03-23 2004-03-28 Gencell Sa Methods for purifying and detecting double stranded dna target sequences by triple helix interaction
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
US7138267B1 (en) 2001-04-04 2006-11-21 Epicentre Technologies Corporation Methods and compositions for amplifying DNA clone copy number
WO2002083889A2 (en) * 2001-04-10 2002-10-24 Imperial College Innovations Limited Methods for the production of minicircles
GB0108968D0 (en) * 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
NZ528003A (en) * 2001-05-30 2006-09-29 Chromos Molecular Systems Inc Platform artificial chromosome expression systems (ACes) containing single or multiple site-specific recombination sites
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
WO2003033723A2 (en) * 2001-10-18 2003-04-24 Aventis Pharmaceuticals Inc. Vectors for expressing multiple transgenes
PT2213730E (pt) 2002-06-18 2016-02-26 Eisai R&D Man Co Ltd Adipócitos de cultura primária para terapia génica
RU2005106999A (ru) * 2002-08-29 2005-08-27 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити (Us) Кольцевые векторы нуклеиновой кислоты и способы их создания и использования
AU2003267175A1 (en) * 2002-09-13 2004-04-30 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
US20040166512A1 (en) * 2002-11-12 2004-08-26 Kahn Michael L. Method for cloning PCR products without restriction or ligation enzymes
AT412400B (de) 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
DE50305146D1 (de) * 2003-06-10 2006-11-02 Mologen Ag Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US20060046294A1 (en) * 2004-08-26 2006-03-02 The United States Of America, As Represented By The Secretary Of Agriculture Site-specific recombination systems for use in eukaryotic cells
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
CN101437547A (zh) * 2005-01-20 2009-05-20 自然科技公司 用于遗传免疫的载体和方法
US8202727B2 (en) * 2005-05-17 2012-06-19 Ozgene Pty Ltd. Sequential cloning system
EP1986698A2 (de) * 2006-02-01 2008-11-05 The Johns Hopkins University Polypeptid-nukleinsäure-konjugat zur immunprophylaxe oder immuntherapie für neoplastische oder infektionskrankheiten
TR201000668T1 (tr) * 2007-07-31 2010-06-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
CA2728291C (en) 2008-07-03 2017-06-20 The Board Of Trustees Of The Leland Stanford Junior University Minicircle dna vector preparations and methods of making and using the same
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
WO2011057825A1 (en) 2009-11-16 2011-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Induction of gene expression in arthropods
DE102009054265A1 (de) 2009-11-16 2011-05-26 Giese, Matthias, Dr. Orale Verabreichung von DNA an Insekten
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
GB201307075D0 (en) 2013-04-19 2013-05-29 Mayrhofer Peter Plasmid for minicircle production
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
MX2022003291A (es) 2019-09-18 2022-09-09 Intergalactic Therapeutics Inc Vectores de adn sinteticos y metodos de uso.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028530A (en) * 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
NZ225470A (en) * 1987-07-21 1990-06-26 Du Pont Stable and viable recombinant viral vectors
FR2631634B1 (fr) * 1988-05-18 1991-06-14 Centre Nat Rech Scient Vecteurs de clonage et d'expression dans une souche d'actinomycete, procede de transformation de cette souche, souche d'actynomycete obtenue et preparation de proteines
US5227288A (en) * 1990-10-01 1993-07-13 Blattner Frederick R DNA sequencing vector with reversible insert
JP3507073B2 (ja) * 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
US5401632A (en) * 1992-07-16 1995-03-28 Wisconsin Alumni Research Foundation Triple helix purification and sequencing
AU5405994A (en) * 1992-10-16 1994-05-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Supercoiled minicircle dna as as a unitary promoter vector
AU1662595A (en) * 1994-01-28 1995-08-15 Herbert Altmann Method of determining the activity of a regulatory factor, and use of the method
FR2715940B1 (fr) * 1994-02-10 1996-04-26 Pasteur Merieux Serums Vacc Procédé de préparation d'une banque multicombinatoire de vecteurs d'expression de gènes d'anticorps, banque et systèmes d'expression d'anticorps "coliclonaux" obtenus.
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique

Also Published As

Publication number Publication date
FR2731014B1 (fr) 1997-03-28
HUP9801216A3 (en) 2001-08-28
ZA961484B (en) 1996-08-28
US6143530A (en) 2000-11-07
CA2211427C (fr) 2010-12-14
SK114397A3 (en) 1998-02-04
JPH11500618A (ja) 1999-01-19
CA2211427A1 (fr) 1996-08-29
EP0815214B1 (de) 2007-07-11
IL117214A0 (en) 1996-06-18
KR19980702406A (ko) 1998-07-15
MX9706109A (es) 1997-11-29
AU709111B2 (en) 1999-08-19
US6492164B1 (en) 2002-12-10
ATE366806T1 (de) 2007-08-15
HUP9801216A2 (hu) 1998-08-28
AU4882296A (en) 1996-09-11
CZ266897A3 (en) 1997-11-12
DE69637156T2 (de) 2008-02-07
BR9607273A (pt) 1998-07-21
FI973467L (fi) 1997-08-22
WO1996026270A1 (fr) 1996-08-29
US20030104444A1 (en) 2003-06-05
FR2731014A1 (fr) 1996-08-30
FI973467A0 (fi) 1997-08-22
NO973838D0 (no) 1997-08-20
NO973838L (no) 1997-10-13
EP0815214A1 (de) 1998-01-07

Similar Documents

Publication Publication Date Title
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
DE69638183D1 (de) Verwendung von nukleinsäureliganden in der durchflusszytometrie
WO2001002568A3 (en) Human genes and gene expression products
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
DE69128893D1 (de) Genetische veränderung von endothelzellen
NO973685L (no) Multi-tumor avvikende vekstgener
DE69432934D1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
ATE290077T1 (de) Regulierte gene und ihre verwendungen
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
DE60031395D1 (de) Mikrobielle beta-glukuronidase gene, genprodukte und deren verwendungen
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
ATE204481T1 (de) Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
FI925359A0 (fi) Kloning och expression av dna-molekyler, som kodar foer arabinandegraderande enzymer av svampursprung
DE69532485D1 (de) Trehalose-freisetzendes Enzym, dafür kodierende DNA, Herstellung und Verwendung
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
ATE427959T1 (de) Gereinigtes sr-p70 protein
DE69931759D1 (de) Methode zur erstellung von genexpressionsprofilen
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
ZA982009B (en) Isolated nucleic acid molecules encoding SSX family members and uses thereof.
EP1124840A4 (de) Ovarspezifische gene und proteine
WO2001098350A3 (en) Compositions comprising net-4 modulations and their use for treating neoplastic disease

Legal Events

Date Code Title Description
8363 Opposition against the patent